Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Verona Pharma Appoints Stifel as Nominated Adviser

Verona Pharma plc
Posted on: 01 Sep 17

LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker with immediate effect.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com
  
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)Tel: +44 (0)20 7710 7600
Stewart Wallace / Jonathan Senior / Ben MaddisonSNELVeronaPharma@stifel.com
  
ICR, Inc. (US Media and Investor Enquiries) 
Darcie RobinsonTel: +1 203 682 8379
 Darcie.Robinson@icrinc.com
Stephanie CarringtonTel: +1 646 277 1282
 Stephanie.Carrington@icrinc.com
  
FTI Consulting (UK Media and Investor Enquiries)Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins
veronapharma@fticonsulting.com


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire
HUG#2130796
GlobeNewswire
globenewswire.com

Last updated on: 04/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.